ONCOMINE™ Again Key to Prostate Cancer Discovery
News Jun 12, 2008
Compendia Bioscience, Inc. has announced the central role of their flagship product Oncomine™ in the discovery and identification of SPINK1 as a key new therapeutic target and biomarker for prostate cancer.
The company believes that the Oncomine is a rapidly growing compendium of nearly 26,000 gene expression and DNA copy number arrays coupled with analysis functions and a web application for data mining and visualization. Comprised of thousands of samples representing every major type of cancer, Oncomine exploits this data for therapeutic target discovery, validation, and prioritization.
Compendia CEO Daniel R. Rhodes, Ph.D., in his continued role as a research investigator at the University of Michigan, led the Oncomine analysis that identified SPINK1 as a candidate oncogene in prostate cancer. Further experimental work by many of the same scientists that previously identified ETS-family gene fusions in prostate cancer using Oncomine led to this discovery.
“We extended an approach called Cancer Outlier Profile Analysis (COPA) that had previously led us to identify ETS-family gene fusions in prostate cancer,” said Dr. Rhodes.
“We knew from that experience that true oncogenes are likely to appear in COPA results from multiple independent datasets. Therefore, we intentionally looked for genes that had high COPA ranks across multiple datasets and SPINK1 looked interesting. Further Oncomine analysis showed that SPINK1 over-expression was mutually exclusive with ETS-family gene fusion events and was not present in normal prostate tissue. So, we were pretty sure we had found something important.”
Published in the current edition of Cancer Cell (Volume 13 Issue 6: June 2008), this study shows that SPINK1 is detectable in the urine and that SPINK1-positive prostate cancers are a particularly aggressive molecular subset of prostate cancer with SPINK1 having a role in cancer invasion.
The analysis approach used to identify SPINK1 has been named Meta-COPA and will soon become a standard feature within the Oncomine platform. In the interim, Compendia Bioscience will provide scientific services to answer customers’ key research questions requiring Meta-COPA or other analyses not currently addressable through the Oncomine user interface.
Researchers Awarded $28M for Illuminating Druggable Genome NIH GrantsNews
Researchers receive grants as part of the NIH program focused on experimental and informatics approaches to characterize understudied proteins from three gene families: ion channels, G protein-coupled receptors (GPCRs), and protein kinases.READ MORE
PhoreMost Completes $15M (£11M) Series-A Round to Enter Drug DiscoveryNews
Investment to fund expansion of operations and progression of drug target pipeline.READ MORE
No Country for Old GenesNews
Our modern world is radically different from the one we evolved in, and that creates a mismatch between the environment our genes were evolved to face, and the world those genes now encounter. A new review looks at how certain genes that benefited humans in our genetic past now predispose us to disease in old age.READ MORE
Comments | 0 ADD COMMENT
9th International Conference on Mass Spectrometry and Chromatography
Sep 21 - Sep 22, 2018